Winfried Wels

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Ahmed Nabil; Salsman Vita S; Yvon Eric; Louis Chrystal U; Perlaky Laszlo; Wels Winfried S; Dishop Meghan K; Kleinerman Eugenie E; Pule Martin; Rooney Cliona M; Heslop Helen E; Gottschalk Stephen
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.
Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels W S; Jäger E; Bader P
WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
Boissel Laurent; Betancur Monica; Wels Winfried S; Tuncer Hande; Klingemann Hans
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Winfried Wels (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Ahmed Nabil; Salsman Vita S; Yvon Eric; Louis Chrystal U; Perlaky Laszlo; Wels Winfried S; Dishop Meghan K; Kleinerman Eugenie E; Pule Martin; Rooney Cliona M; Heslop Helen E; Gottschalk Stephen
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression.
Molecular therapy : the journal of the American Society of Gene Therapy 2009;17(10):1779-87.
2009: Weber G; Karbach J; Kuçi S; Kreyenberg H; Willasch A; Koscielniak E; Tonn T; Klingebiel T; Wels W S; Jäger E; Bader P
WT1 peptide-specific T cells generated from peripheral blood of healthy donors: possible implications for adoptive immunotherapy after allogeneic stem cell transplantation.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 2009;23(9):1634-42.
2009: Boissel Laurent; Betancur Monica; Wels Winfried S; Tuncer Hande; Klingemann Hans
Transfection with mRNA for CD19 specific chimeric antigen receptor restores NK cell mediated killing of CLL cells.
Leukemia research 2009;33(9):1255-9.
2009: Mahmud Hayat; Dälken Benjamin; Wels Winfried S
Induction of programmed cell death in ErbB2/HER2-expressing cancer cells by targeted delivery of apoptosis-inducing factor.
Molecular cancer therapeutics 2009;8(6):1526-35.
2009: Tavri Sidhartha; Jha Priyanka; Meier Reinhard; Henning Tobias D; Müller Tina; Hostetter Daniel; Knopp Christiane; Johansson Magnus; Reinhart Verena; Boddington Sophie; Sista Akhilesh; Wels Winfried S; Daldrup-Link Heike E
Optical imaging of cellular immunotherapy against prostate cancer.
Molecular imaging : official journal of the Society for Molecular Imaging 2009;8(1):15-26.
2008: Sloots Arjen; Mastini Cristina; Rohrbach Florian; Weth Robert; Curcio Claudia; Burkhardt Ute; Jäger Elke; Forni Guido; Cavallo Federica; Wels Winfried S
DNA vaccines targeting tumor antigens to B7 molecules on antigen-presenting cells induce protective antitumor immunity and delay onset of HER-2/Neu-driven mammary carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):6933-43.
2008: Michaelis Martin; Bliss Jennifer; Arnold Sonja C; Hinsch Nora; Rothweiler Florian; Deubzer Hedwig E; Witt Olaf; Langer Klaus; Doerr Hans W; Wels Winfried S; Cinatl Jindrich
Cisplatin-resistant neuroblastoma cells express enhanced levels of epidermal growth factor receptor (EGFR) and are sensitive to treatment with EGFR-specific toxins.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(20):6531-7.
2008: Meier Reinhard; Piert Morand; Piontek Guido; Rudelius Martina; Oostendorp Robert A; Senekowitsch-Schmidtke Reingard; Henning Tobias D; Wels Winfried S; Uherek Christoph; Rummeny Ernst J; Daldrup-Link Heike E
Tracking of [18F]FDG-labeled natural killer cells to HER2/neu-positive tumors.
Nuclear medicine and biology 2008;35(5):579-88.
2008: Müller Tina; Uherek Christoph; Maki Guitta; Chow Kai Uwe; Schimpf Annemarie; Klingemann Hans-Georg; Tonn Torsten; Wels Winfried S
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.
Cancer immunology, immunotherapy : CII 2008;57(3):411-23.
2007: Mazor Yariv; Noy Roy; Wels Winfried S; Benhar Itai
chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
Cancer letters 2007;257(1):124-35.
2007: Kirkin V; Cahuzac N; Guardiola-Serrano F; Huault S; Lückerath K; Friedmann E; Novac N; Wels W S; Martoglio B; Hueber A-O; Zörnig M
The Fas ligand intracellular domain is released by ADAM10 and SPPL2a cleavage in T-cells.
Cell death and differentiation 2007;14(9):1678-87.
2007: Klöss Stephan; Bochennek Konrad; Huenecke Sabine; Zimmermann Stefanie-Yvonne; Kuçi Selim; Müller Tina; Wels Winfried S; Klingebiel Thomas; Esser Ruth; Koehl Ulrike
A novel five-colour flow cytometric assay to determine NK cell cytotoxicity against neuroblastoma and other adherent tumour cells.
Journal of immunological methods 2007;325(1-2):140-7.
2007: Ahmed Nabil; Ratnayake Maheshika; Savoldo Barbara; Perlaky Laszlo; Dotti Gianpietro; Wels Winfried S; Bhattacharjee Meenakshi B; Gilbertson Richard J; Shine H David; Weiss Heidi L; Rooney Cliona M; Heslop Helen E; Gottschalk Stephen
Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
Cancer research 2007;67(12):5957-64.
2007: Singh Ravibhushan; Samant Urmila; Hyland Stephen; Chaudhari Pradip R; Wels Winfried S; Bandyopadhyay Dilip
Target-specific cytotoxic activity of recombinant immunotoxin scFv(MUC1)-ETA on breast carcinoma cells and primary breast tumors.
Molecular cancer therapeutics 2007;6(2):562-9.
2007: Novak Hila; Noy Roy; Oved Kfir; Segal Dina; Wels Winfried S; Reiter Yoram
Selective antibody-mediated targeting of class I MHC to EGFR-expressing tumor cells induces potent antitumor CTL activity in vitro and in vivo.
International journal of cancer. Journal international du cancer 2007;120(2):329-36.
2006: Dälken B; Giesübel U; Knauer S K; Wels W S
Targeted induction of apoptosis by chimeric granzyme B fusion proteins carrying antibody and growth factor domains for cell recognition.
Cell death and differentiation 2006;13(4):576-85.
2006: Giesübel Ulrike; Dälken Benjamin; Mahmud Hayat; Wels Winfried S
Cell binding, internalization and cytotoxic activity of human granzyme B expressed in the yeast Pichia pastoris.
The Biochemical journal 2006;394(Pt 3):563-73.
2006: Heurtault Béatrice; Thomann Jean-Sébastien; Jedrzejewska Justyna; Wels Winfried S; Schuber Francis; Frisch Benoît
Liposome-based systems for anti-tumor vaccination: influence of lipopeptide adjuvants.
Journal of liposome research 2006;16(3):205-13.
2005: Sloots Arjen; Wels Winfried S
Recombinant derivatives of the human high-mobility group protein HMGB2 mediate efficient nonviral gene delivery.
The FEBS journal 2005;272(16):4221-36.
2005: Shaki-Loewenstein Shelly; Zfania Rahely; Hyland Stephen; Wels Winfried S; Benhar Itai
A universal strategy for stable intracellular antibodies.
Journal of immunological methods 2005;303(1-2):19-39.
2005: Rohrbach Florian; Weth Robert; Kursar Mischo; Sloots Arjen; Mittrücker Hans-Willi; Wels Winfried S
Targeted delivery of the ErbB2/HER2 tumor antigen to professional APCs results in effective antitumor immunity.
Journal of immunology (Baltimore, Md. : 1950) 2005;174(9):5481-9.
2005: Roth A; Rohrbach F; Weth R; Frisch B; Schuber F; Wels W S
Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct.
British journal of cancer 2005;92(8):1421-9.
2005: Biburger Markus; Weth Robert; Wels Winfried S
A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.
Journal of molecular biology 2005;346(5):1299-311.
2005: Daldrup-Link Heike E; Meier Reinhardt; Rudelius Martina; Piontek Guido; Piert Morand; Metz Stephan; Settles Marcus; Uherek Christoph; Wels Winfried; Schlegel Jürgen; Rummeny Ernst J
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging.
European radiology 2005;15(1):4-13.
2005: von Minckwitz Gunter; Harder Sebastian; Hövelmann Sascha; Jäger Elke; Al-Batran Salah-Eddin; Loibl Sibylle; Atmaca Akin; Cimpoiasu Christian; Neumann Antje; Abera Aklil; Knuth Alexander; Kaufmann Manfred; Jäger Dirk; Maurer Alexander B; Wels Winfried S
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas.
Breast cancer research : BCR 2005;7(5):R617-26.
2004: Groner Bernd; Hartmann Cord; Wels Winfried
Therapeutic antibodies.
Current molecular medicine 2004;4(5):539-47.
2004: Wels Winfried; Biburger Markus; Müller Tina; Dälken Benjamin; Giesübel Ulrike; Tonn Torsten; Uherek Christoph
Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors.
Cancer immunology, immunotherapy : CII 2004;53(3):217-26.
2003: Azemar Marc; Djahansouzi Sirus; Jäger Elke; Solbach Christine; Schmidt Mathias; Maurer Alexander B; Mross Klaus; Unger Clemens; von Minckwitz Gunter; Dall Peter; Groner Bernd; Wels Winfried S
Regression of cutaneous tumor lesions in patients intratumorally injected with a recombinant single-chain antibody-toxin targeted to ErbB2/HER2.
Breast cancer research and treatment 2003;82(3):155-64.
2003: Hyland Stephen; Beerli Roger R; Barbas Carlos F; Hynes Nancy E; Wels Winfried
Generation and functional characterization of intracellular antibodies interacting with the kinase domain of human EGF receptor.
Oncogene 2003;22(10):1557-67.
2002: Erlwein Otto; Wels Winfried; Schnierle Barbara S
Chimeric ecotropic MLV envelope proteins that carry EGF receptor-specific ligands and the Pseudomonas exotoxin A translocation domain to target gene transfer to human cancer cells.
Virology 2002;302(2):333-41.
2002: Gaur Reetika; Gupta Pradeep K; Goyal Anita; Wels Winfried; Singh Yogendra
Delivery of nucleic acid into mammalian cells by anthrax toxin.
Biochemical and biophysical research communications 2002;297(5):1121-7.
2002: Uherek Christoph; Tonn Torsten; Uherek Barbara; Becker Sven; Schnierle Barbara; Klingemann Hans-Georg; Wels Winfried
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.
Blood 2002;100(4):1265-73.
2002: Schmidt Mathias; Wels Winfried
Replacement of N-terminal portions of TGF-alpha with corresponding heregulin sequences affects ligand-induced receptor signaling and intoxication of tumor cells by chimeric growth-factor toxins.
International journal of cancer. Journal international du cancer 2002;97(3):349-56.
2002: Moradpour Darius; Bieck Elke; Hügle Thomas; Wels Winfried; Wu Jim Zhen; Hong Zhi; Blum Hubert E; Bartenschlager Ralf
Functional properties of a monoclonal antibody inhibiting the hepatitis C virus RNA-dependent RNA polymerase.
The Journal of biological chemistry 2002;277(1):593-601.
2001: Uherek C; Groner B; Wels W
Chimeric antigen receptors for the retargeting of cytotoxic effector cells.
Journal of hematotherapy & stem cell research 2001;10(4):523-34.
2000: Rohrbach F; Gerstmayer B; Biburger M; Wels W
Construction and characterization of bispecific costimulatory molecules containing a minimized CD86 (B7-2) domain and single-chain antibody fragments for tumor targeting.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(11):4314-22.
2000: Uherek C; Wels W
DNA-carrier proteins for targeted gene delivery.
Advanced drug delivery reviews 2000;44(2-3):153-66.
2000: Benhar I; Azriel R; Nahary L; Shaky S; Berdichevsky Y; Tamarkin A; Wels W
Highly efficient selection of phage antibodies mediated by display of antigen as Lpp-OmpA' fusions on live bacteria.
Journal of molecular biology 2000;301(4):893-904.
2000: Azemar M; Schmidt M; Arlt F; Kennel P; Brandt B; Papadimitriou A; Groner B; Wels W
Recombinant antibody toxins specific for ErbB2 and EGF receptor inhibit the in vitro growth of human head and neck cancer cells and cause rapid tumor regression in vivo.
International journal of cancer. Journal international du cancer 2000;86(2):269-75.
1999: Schmidt M; Maurer-Gebhard M; Groner B; Köhler G; Brochmann-Santos G; Wels W
Suppression of metastasis formation by a recombinant single chain antibody-toxin targeted to full-length and oncogenic variant EGF receptors.
Oncogene 1999;18(9):1711-21.
1999: Maurer-Gebhard M; Schmidt M; Azemar M; Stöcklin E; Wels W; Groner B
A novel animal model for the evaluation of the efficacy of drugs directed against the ErbB2 receptor on metastasis formation.
Hybridoma 1999;18(1):69-75.
1998: Hoffmann M; Schmidt M; Wels W
Activation of EGF receptor family members suppresses the cytotoxic effects of tumor necrosis factor-alpha.
Cancer immunology, immunotherapy : CII 1998;47(3):167-75.
1998: Maurer-Gebhard M; Schmidt M; Azemar M; Altenschmidt U; Stöcklin E; Wels W; Groner B
Systemic treatment with a recombinant erbB-2 receptor-specific tumor toxin efficiently reduces pulmonary metastases in mice injected with genetically modified carcinoma cells.
Cancer research 1998;58(12):2661-6.
1998: Fominaya J; Uherek C; Wels W
A chimeric fusion protein containing transforming growth factor-alpha mediates gene transfer via binding to the EGF receptor.
Gene therapy 1998;5(4):521-30.
1998: Uherek C; Fominaya J; Wels W
A modular DNA carrier protein based on the structure of diphtheria toxin mediates target cell-specific gene delivery.
The Journal of biological chemistry 1998;273(15):8835-41.
1998: Schmidt M; Reiser P; Hills D; Gullick W J; Wels W
Expression of an oncogenic mutant EGF receptor markedly increases the sensitivity of cells to an EGF-receptor-specific antibody-toxin.
International journal of cancer. Journal international du cancer 1998;75(6):878-84.
1998: Spyridonidis A; Schmidt M; Bernhardt W; Papadimitriou A; Azemar M; Wels W; Groner B; Henschler R
Purging of mammary carcinoma cells during ex vivo culture of CD34+ hematopoietic progenitor cells with recombinant immunotoxins.
Blood 1998;91(5):1820-7.
1997: Gerstmayer B; Hoffmann M; Altenschmidt U; Wels W
Costimulation of T-cell proliferation by a chimeric B7-antibody fusion protein.
Cancer immunology, immunotherapy : CII 1997;45(3-4):156-8.
1997: Altenschmidt U; Schmidt M; Groner B; Wels W
Targeted therapy of schwannoma cells in immunocompetent rats with an erbB2-specific antibody-toxin.
International journal of cancer. Journal international du cancer 1997;73(1):117-24.
1997: Gerstmayer B; Altenschmidt U; Hoffmann M; Wels W
Costimulation of T cell proliferation by a chimeric B7-2 antibody fusion protein specifically targeted to cells expressing the erbB2 proto-oncogene.
Journal of immunology (Baltimore, Md. : 1950) 1997;158(10):4584-90.
1997: Gerstmayer B; Pessara U; Wels W
Construction and expression in the yeast Pichia pastoris of functionally active soluble forms of the human costimulatory molecules B7-1 and B7-2 and the B7 counter-receptor CTLA-4.
FEBS letters 1997;407(1):63-8.
1997: Zimmermann S; Wels W; Froesch B A; Gerstmayer B; Stahel R A; Zangemeister-Wittke U
A novel immunotoxin recognising the epithelial glycoprotein-2 has potent antitumoural activity on chemotherapy-resistant lung cancer.
Cancer immunology, immunotherapy : CII 1997;44(1):1-9.
1997: Groner B; Wick B; Jeschke M; Fiebig H H; Dengler W; Runau T; Mihatsch M; Kahl R; Schmidt M; Wels W; Stöcklin E
Intra-tumoral application of a heregulin-exotoxin-a fusion protein causes rapid tumor regression without adverse systemic or local effects.
International journal of cancer. Journal international du cancer 1997;70(6):682-7.
1997: Schmidt M; Vakalopoulou E; Schneider D W; Wels W
Construction and functional characterization of scFv(14E1)-ETA - a novel, highly potent antibody-toxin specific for the EGF receptor.
British journal of cancer 1997;75(11):1575-84.
1996: Hekele A; Dall P; Moritz D; Wels W; Groner B; Herrlich P; Ponta H
Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scFv:zeta-chimera.
International journal of cancer. Journal international du cancer 1996;68(2):232-8.
1996: Altenschmidt U; Kahl R; Moritz D; Schnierle B S; Gerstmayer B; Wels W; Groner B
Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(6):1001-8.
1996: Fominaya J; Wels W
Target cell-specific DNA transfer mediated by a chimeric multidomain protein. Novel non-viral gene delivery system.
The Journal of biological chemistry 1996;271(18):10560-8.
1996: Schmidt M; Hynes N E; Groner B; Wels W
A bivalent single-chain antibody-toxin specific for ErbB-2 and the EGF receptor.
International journal of cancer. Journal international du cancer 1996;65(4):538-46.
1996: Beerli R R; Wels W; Hynes N E
Inhibition of signaling from Type 1 receptor tyrosine kinases via intracellular expression of single-chain antibodies.
Breast cancer research and treatment 1996;38(1):11-7.
1996: Wels W; Groner B; Hynes N E
Intervention in receptor tyrosine kinase-mediated pathways: recombinant antibody fusion proteins targeted to ErbB2.
Current topics in microbiology and immunology 1996;213 ( Pt 3)():113-28.
1995: Wels W; Moritz D; Schmidt M; Jeschke M; Hynes N E; Groner B
Biotechnological and gene therapeutic strategies in cancer treatment.
Gene 1995;159(1):73-80.
1995: Jeschke M; Wels W; Dengler W; Imber R; Stöcklin E; Groner B
Targeted inhibition of tumor-cell growth by recombinant heregulin-toxin fusion proteins.
International journal of cancer. Journal international du cancer 1995;60(5):730-9.
1995: Wels W; Beerli R; Hellmann P; Schmidt M; Marte B M; Kornilova E S; Hekele A; Mendelsohn J; Groner B; Hynes N E
EGF receptor and p185erbB-2-specific single-chain antibody toxins differ in their cell-killing activity on tumor cells expressing both receptor proteins.
International journal of cancer. Journal international du cancer 1995;60(1):137-44.
1994: Beerli R R; Wels W; Hynes N E
Autocrine inhibition of the epidermal growth factor receptor by intracellular expression of a single-chain antibody.
Biochemical and biophysical research communications 1994;204(2):666-72.
1994: Beerli R R; Wels W; Hynes N E
Intracellular expression of single chain antibodies reverts ErbB-2 transformation.
The Journal of biological chemistry 1994;269(39):23931-6.
1994: Moritz D; Wels W; Mattern J; Groner B
Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(10):4318-22.
1993: Harwerth I M; Wels W; Schlegel J; Müller M; Hynes N E
Monoclonal antibodies directed to the erbB-2 receptor inhibit in vivo tumour cell growth.
British journal of cancer 1993;68(6):1140-5.
1992: Wels W; Harwerth I M; Mueller M; Groner B; Hynes N E
Selective inhibition of tumor cell growth by a recombinant single-chain antibody-toxin specific for the erbB-2 receptor.
Cancer research 1992;52(22):6310-7.
1992: Wels W; Harwerth I M; Zwickl M; Hardman N; Groner B; Hynes N E
Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor.
Bio/technology (Nature Publishing Company) 1992;10(10):1128-32.
1992: Wels W; Harwerth I M; Hynes N E; Groner B
Diminution of antibodies directed against tumor cell surface epitopes: a single chain Fv fusion molecule specifically recognizes the extracellular domain of the c-erbB-2 receptor.
The Journal of steroid biochemistry and molecular biology 1992;43(1-3):1-7.
1992: Harwerth I M; Wels W; Marte B M; Hynes N E
Monoclonal antibodies against the extracellular domain of the erbB-2 receptor function as partial ligand agonists.
The Journal of biological chemistry 1992;267(21):15160-7.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Winfried Wels

Research Profile (preview)

Chemicals & Drugs

Living Beings

Anatomy

Concepts & Ideas

Genes & Molecular Sequences

Disorders

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Winfried Wels (preview)

All Publications